BioScrip, Inc. (NASDAQ:BIOS) Director Coliseum Capital Management, L sold 2,846,941 shares of BioScrip stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $2.93, for a total value of $8,341,537.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Coliseum Capital Management, L also recently made the following trade(s):

  • On Thursday, August 17th, Coliseum Capital Management, L sold 886,478 shares of BioScrip stock. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24.

BioScrip, Inc. (NASDAQ BIOS) traded down 2.74% during trading on Thursday, hitting $2.84. The stock had a trading volume of 4,595,093 shares. BioScrip, Inc. has a 12 month low of $0.98 and a 12 month high of $3.43. The stock’s market cap is $362.03 million. The stock has a 50 day moving average price of $2.91 and a 200-day moving average price of $2.22.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01. The business had revenue of $218.11 million during the quarter, compared to the consensus estimate of $220.05 million. The firm’s revenue for the quarter was down 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.14) EPS. On average, equities analysts predict that BioScrip, Inc. will post ($0.55) EPS for the current year.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/07/bioscrip-inc-bios-director-sells-8341537-13-in-stock.html.

A number of equities analysts have commented on BIOS shares. Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Jefferies Group LLC reissued a “buy” rating and set a $4.00 target price (up from $3.00) on shares of BioScrip in a research note on Thursday, August 10th. ValuEngine cut BioScrip from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. BidaskClub cut BioScrip from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 1st. Finally, SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and boosted their target price for the company from $3.25 to $3.75 in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $3.75.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors purchased a new position in BioScrip during the 2nd quarter worth $123,000. Voya Investment Management LLC increased its holdings in BioScrip by 41.4% during the 2nd quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after purchasing an additional 14,867 shares during the period. Goldman Sachs Group Inc. increased its holdings in BioScrip by 65.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock worth $109,000 after purchasing an additional 25,500 shares during the period. American International Group Inc. increased its holdings in BioScrip by 73.8% during the 1st quarter. American International Group Inc. now owns 67,812 shares of the company’s stock worth $115,000 after purchasing an additional 28,787 shares during the period. Finally, Alambic Investment Management L.P. purchased a new position in BioScrip during the 1st quarter worth $160,000. Institutional investors own 84.15% of the company’s stock.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.